Jeito Capital announces the acquisition by Merck & Co (NYSE:MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress achieved with Restoret™, EyeBio's novel late-phase candidate for diabetic macular edema, as well as a preclinical pipeline targeting retinal diseases - Restoret anticipated to enter pivotal study for diabetic macular edema in the second half of 2024 The acquisition by Merck & Co (NYSE:MRK), a global biopharmaceutical c ...

A month has gone by since the last earnings report for Biogen Inc. (BIIB) . Shares have added about 7.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Biogen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q1 Earnings Beat, Sales MissBiogen’s first-quarter results ...

NEW YORK, May 23, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ: BIIB) and certain of its officers.Class Definition:This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Biogen Inc. securi ...

LOS ANGELES, May 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are en ...

Biogen (BIIB) entered into a definitive agreement to acquire private biotech, HI-Bio, for a $1.15 billion upfront payment.The acquisition will expand Biogen’s rare disease pipeline by adding Hi-Bio’s lead candidate, felzartamab, a promising late-stage ready asset with potential application across a range of rare immune-mediated diseases. Felzartamab, a fully human anti-CD38 monoclonal antibody, has demonstrated an impact on key biomarkers and clinical endpoints in three renal diseases.Felzartamab is being d ...

Key TakeawaysBiogen has agreed to pay at least $1.15 billion for biotech firm Human Immunology Biosciences (HI-Bio) as it moves to increase its immunology portfolio.The deal includes the possibility of an additional $650 million in milestone payments. HI-Bio's lead asset treats rare kidney diseases. Biogen (BIIB) announced Wednesday it had purchased privately-held Human Immunology Biosciences (HI-Bio) for at least $1.15 billion to expand its reach into immunology medicines.  The company said that the $1.15 ...

NEW YORK, May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the"Company") (NASDAQ: BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv-01444, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biogen securities between February 3, 2022 and February 13, 2024, both dates i ...

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences expertise ...

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences expertise ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?Developed alongs ...